tbuckley/cabot-search huggingface dataset:
SAT0122 Comorbidities in A Mexican Mestizo Cohort of Patients with Early Rheumatoid Arthritis
Authors: L. Pérez-Barbosa, I.J. Colunga-Pedraza, J.C. Riega-Torres, R.I. Arvizu-Rivera, A. Martínez-Moreno, F.J. Torres-Quintanilla, M.A. Garza-Elizondo
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Patients with rheumatoid arthritis (RA) are at an increased risk of comorbidities and it has been linked to a decrease in life expectancy in comparison with the general population. Early recognition and treatment of comorbidities is important. <h3>Objectives</h3> We aimed to evaluate the presence of comorbidities in a Mexican mestizo cohort of patients with early-RA. <h3>Methods</h3> A descriptive, cross-sectional study of patients with early-rheumatoid arthritis (disease duration &lt;12 months) was designed. Information on comorbidities, weight, height and body mass index (BMI) was collected. <h3>Results</h3> Data of fifty patients was included in the final analysis, 46 (92.0%) of them were women. Patient9s characteristics are shown in Table 1. Mean age was 44.3 ± 13.12 years. Mean disease duration was 6.09 ± 2.91 months. Tuberculosis (TB) infection was found in 12 (24.0%) patients, 7 (58.3%) of them were latent tuberculosis infection. Four cases of extra-pulmonary TB were reported. Hypertension was the second most prevalent comorbidity, being reported in 11 (22.0%) patients. <h3>Conclusions</h3> In this cohort of Mexican mestizo patients with early-RA, TB infection was found in 24.0% of the patients. Hypertension was the second most prevalent comorbidity in our cohort, being reported in 22.0% of the patients. Other cardiovascular heart disease risk factors were also reported. Early recognition of these comorbidities is needed because of the higher risk of cardiovascular heart disease in RA-patients in comparison to the general population. <h3>References</h3> Emery, P., Breedveld, F. C., Dougados, M., Kalden, J. R., Schiff, M. H., &amp; Smolen, J. S. (2002). Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Annals of the rheumatic diseases, 61(4), 290–297. <h3>Disclosure of Interest</h3> None declared
SP0009 Patients' View on The Eular Recommendations
Authors: N. Caeyers
Journal: Annals of the Rheumatic Diseases (2016)

The use of glucocorticoids has always had a negative connotation among patients. Within the general public the beliefs still stand that the side effects cause more harm than that this medication is helping the patient. Pressure from the environment also keeps people away from the treatment with GC, as well as confrontation with visible side effects. But not only patients, also some health professionals tend to believe GC are more harmful than good. They are especially reluctant to prescribe high doses, although for some conditions this could be lifesaving. Patients often do a Google search on the internet when prescribed new medication. Reading these awful stories, having doubtful information and the pressure from their peers and consulting a doctor who is not convinced of the benefits of GC, might make them refuse to start treatment. The EULAR recommendations on the use of GC can help change this perception among patients9 and clinicians9 communities. These recommendations are now available in a lay version which means also people with a non-medical background can read and understand the important messages. To change the view of patients, but also GP9s and other health care professionals, it would be worthwhile to spread this information. Patient and scientific organisations can play an important role in the implementation. In Flanders, we have already made the translation and put the lay version on the website, together with the original manuscript. Some quotes of people who have read the recommendations show these guidelines are also valuable for patients. “Finally, this is medical information that I can understand! This is useful for me” “These recommendations give information in a clear and comprehensive way. They allow me to contribute in the process to get the best possible care for me. I can now make well-informed decisions and can ask more direct questions to my rheumatologist.” “It is nice to know patients were involved in developing these recommendations. This means also our concerns were heard.” This lecture will feature results of a survey among Flemish and Dutch patients about their view on GC as well as their ideas to use lay versions of scientific publications. <h3>Disclosure of Interest</h3> None declared
Multiple Myeloma with Prior Precursor Disease Shows Better Outcome
Authors: Rafael Ríos-Tamayo, Juan Sáinz Pérez, Manuel Jurado, Jose Manuel Puerta Puerta, Pedro Antonio González Sierra, Antonio Romero Aguilar, Elisa Lopez Fernandez, Lucia Moratalla Lopez, José Luís García de Veas Silva, Teresa Rodríguez Ruiz, José Juan Jiménez Moleón, María José Sánchez Pérez
Journal: Blood (2015)
Reduced Intensity Versus Conventional Myeloablative Conditioning (RIC vs. MAC) Allogeneic Stem Cell Transplantation (allo-SCT) for Patients with Acute Lymphoblastic Leukemia (ALL): A Survey from the Acute Leukemia Working Party of EBMT
Authors: Mohamad Mohty, Myriam Labopin, Tapani Ruutu, Alois Gratwohl, Gerard Socie, Jordi Esteve, Reza Tabrizi, Arnon Nagler, Vanderson Rocha
Journal: Blood (2008)
High Resolution Genomic Profiling of Primary “Ultra High Risk” and Refractory Chronic Lymphocytic Leukemia: Results from the CLL2O Trial
Authors: Jennifer Edelmann, Jenny Saub, Stefan Ibach, Karlheinz Holzmann, Eugen Tausch, Johannes Bloehdorn, Daniel Mertens, Thorsten Zenz, Florence Cymbalista, Veronique Leblond, Alain Delmer, John G. Gribben, Michael Hallek, Hartmut Döhner, Stephan Stilgenbauer
Journal: Blood (2014)
AB0830 Iron Metabolism: Association of Ferritin with Serum Urate and Gout
Authors: T. Fatima, T. Merriman, C. Iverson, J.N. Miner
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Iron homeostasis is a tightly regulated set of biochemical processes. Transferrin and its cell-surface receptor regulate iron uptake and ferritin sequesters free iron and acts as a store for excess iron from intra- and extra-cellular pools. Ferritin has been positively associated with serum urate in the National Health and Nutrition Examination Survey III (NHANES III) [1]. There have been observational and interventional studies suggesting a role for iron as a trigger for gout flares, which may be due to a number of pro-inflammatory activities associated with iron [2, 3]. Consistent with this, genetic variation in the transferrin receptor is associated with gout and with an increased likelihood of self-report of an iron-rich food as a trigger of flares [2]. Genetic variation in the transferrin receptor is associated with gout and with an increased likelihood of self-report of an iron-rich food as a trigger of flares [2]. <h3>Objectives</h3> To replicate the association of ferritin with serum urate and to test for association of ferritin with gout. <h3>Methods</h3> For the serum urate association analysis, African-American subjects from the publicly available Jackson Heart Study were included (693 females and 567 males). Subjects who self-reported taking diuretic or urate-lowering medication/s, or who had kidney disease or gout, were excluded. For the gout analysis 93 individuals were included, comprising 60 controls (all males) and 33 gout cases (4 females and 29 males). Linear regression analysis using R 3.2.0 and adjusting for age and body mass index was done to test for association between ferritin and serum urate. An unpaired <i>t</i> test was used to test for association between gout and plasma ferritin. <h3>Results</h3> A positive association of serum ferritin and urate was found in both males (β=1.02E-04 pmol/L, <i>P</i>=9.6E-03) and females (β=1.95E-04pmol/L, <i>P</i>=7.1E-04) in the Jackson Heart Study. Plasma concentrations of ferritin were elevated in gout cases (Mean±SD; 320.6±167.1 ng/mL) compared to controls (69.45±63.41 ng/mL) (<i>P</i>&lt;1x10<sup>–4</sup>). <h3>Conclusions</h3> The associations between ferritin and both serum urate and gout implicate iron metabolism in gout. While it is not possible to assign causality from this observational study, the previously reported association of the transferrin receptor with gout [1] is consistent with iron metabolism having a causal role in gout. <h3>References</h3> Ghio AJ, et al. Free Radic Res. 2005;39(3):337–342. Facchini FS. Rheumatology. 2003;42:1550–1555. Dabbagh AJ, et al. Ann Rheum Dis. 1992;51:516–21. <h3>Acknowledgement</h3> Research sponsored by Ardea Biosciences/AstraZeneca. Editorial support was provided by PAREXEL and funded by AstraZeneca. <h3>Disclosure of Interest</h3> T. Fatima: None declared, T. Merriman Grant/research support from: Ardea Biosciences, Inc., C. Iverson Employee of: Ardea Biosciences, Inc., J. Miner Employee of: Ardea Biosciences, Inc.
AML-M4: Role of Eosinophilia and Cytogenetics on Treatment Response and Survival. The GIMEMA Experience.
Authors: Alessandro Pulsoni, Simona Iacobelli, Paola Fazi, Paolo Falcucci, Marco Vignetti, Maria Elena Tosti, Giovanna Caterina Valentini, Silvana Magrin, Felicetto Ferrara, Lorella Melillo, Francesco Di Raimondo, Marco Sborgia, Adriano Venditti, Andrea Camera, Vincenzo Liso, Giorgina Specchia, Giuseppe Leone, Franco Mandelli, Robert Foa, Livio Pagano
Journal: Blood (2005)
AB0482 Evaluation of Current and at The Onset Clinical Manifestations in Systemic Lupus Erythematosus Patients:
Authors: M. Fernández Matilla, E. Grau García, G. Poveda Marín, C. Feced Olmos, E. Labrador Sánchez, F.M. Ortiz Sanjuan, D. Hervás Marín, N. Fernández-Llanio, V. Fornes Ferrer, K. Arévalo Ruales, R. Negueroles Albuixech, J. Ivorra Cortés, J. Fragio Gil, I. Martínez Cordellat, J. Valero Sanz, I. Chalmeta Verdejo, L. González Puig, C. Alcañiz Escandell, C. Nájera Herranz, J. Castellano Cuesta, J. Román Ivorra
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Systemic Lupus Erythematosus (SLE) in a multisystemic autoimmune disease that specially affects young women during the second and third decade, and is able to injure different organs and or systems, being the most common one affected the musculoskeletal system. <h3>Objectives</h3> To analyse the influence of the time of evolution and age of the patient in the current clinical manifestations and the debut of the disease in patients with SLE. <h3>Methods</h3> Cross-sectional prospective study of SLE patients according to the SLICC-2012 criteria, coming from the Rheumatology Service of Arnau de Vilanova Hospital and La Fe Hospital. All patients had a complete blood-test with autoimmunity markers, and clinical, biometrics and treatment data were also collected from the personal interview and the medical history. Biostatistical analysis was performed using the <i>R</i> software version 3.2.3., using a simple, binomial and logistic lineal regression. <h3>Results</h3> A total of 140 patients were evaluated; of them, (95% were women) with 33.39±13.63 year-old average at the diagnosis time with a 10.05±11.42 year-evolution of SLE. We can find the clinical manifestations at the onset disease on the table. We observe statistically significant differences in the musculoskeletal system involvement (P=0.008), and in the presence of vasculitis (P=0.01) in patients with a shorter time of disease evolution. There is also a direct relationship between cardiovascular (P=0.002) and renal (P=0.03) affection in younger patients. Finally, cytopenias are correlated both in young patients (P=0.0009) as well as with a shorter time of evolution (P=0.02). <h3>Conclusions</h3> We observe a concordance between our SLE series and those already described at the literature, where renal involvement occurs at younger ages, and the musculoskeletal system involvement occurs early in disease or even as the onset symptom. <h3>Disclosure of Interest</h3> None declared
Granulocyte JAK2 (V617F) Mutation Status in Myeloid Neoplasms with Ringed Sideroblasts.
Authors: Luca Malcovati, Matteo G. Della Porta, Daniela Pietra, Anna Galli, Erica Travaglino, Elisa Rumi, Rosangela Invernizzi, Francesco Passamonti, Mario Lazzarino, Mario Cazzola
Journal: Blood (2006)
Efficacy of Administration of Plerixafor (Mozobil®) at 5:00 PM for Stem Cell Mobilization (SCM) in Patients Receiving Autologous Stem Cell Transplant.
Authors: Jennifer Tornatta, John J. Maciejewski, Sunita Nathan, Bruce C. McLeod, Darilyn Rhoades, Sridevi Palaparthy, Henry C. Fung
Journal: Blood (2009)
The burden of nonadherence among adults with asthma: a role for shared decision‐making
Authors: S. Pollard, N. Bansback, J. M. FitzGerld, S. Bryan
Journal: Allergy (2016)

Abstract A shared approach to decision‐making framework has been suggested for chronic disease management especially where multiple treatment options exist. Shared decision‐making ( SDM ) requires that both physician and patients are actively engaged in the decision‐making process, including information exchange; expressing treatment preferences; as well as agreement over the final treatment decision. Although SDM appears well supported by patients, practitioners and policymakers alike, the current challenge is to determine how best to make SDM a reality in everyday clinical practice. Within the context of asthma, adherence rates are poor and are linked to outcomes such as reduced asthma control, increased symptoms, healthcare expenditures, and lower patient quality of life. It has been suggested that SDM can improve treatment adherence and that ignoring patients’ personal goals and preferences may result in reduced rates of adherence. Furthermore, understanding predictors of poor treatment adherence is a necessary step toward developing effective strategies to improve the patient‐reported and clinically important outcomes. Here, we describe why a shared approach to treatment decision‐making for asthma has the potential to be an effective tool for improving adherence, with associated clinical and patient‐related outcomes. In addition, we explore insights into the reasons why SDM has not been implemented into routine clinical practice.
Traumatic Lumbar Puncture (TLP) Is Not Associated with Worse Outcome in Adults with Acute Lymphocytic Leukemia (ALL) or Burkitt-Type Leukemia/Lymphoma (BLL) Receiving Hyper-CVAD Regimens.
Authors: Ehab Atallah, Susan O’Brien, Susan Kaled, Alice Lynn, Jorge Cortes, Hagop Kantarjian, Deborah A. Thomas
Journal: Blood (2007)
Inflammatory Cytokine Levels in the Peri-Stem Cell Transplantation Period Correlate with Fluctuations in Peripheral Blood Counts but Not with Inflammation.
Authors: J. Joseph Melenhorst, Angelique Biancotto, Phillip Scheinberg, Colin O. Wu, J. Philip McCoy, Priscila Scheinberg, Nancy F Hensel, A. John Barrett
Journal: Blood (2008)
Time to Failure and CD3-Expression Are Strong Prognostic Factors in Relapsed Anaplastic Large Cell Lymphoma of Childhood and Adolescence.
Authors: Wilhelm Woessmann, Meike Lenhard, Christina Peters, Birgit Burkhardt, Wolgang Ebell, Thomas Klingebiel, Georg Mann, Johann Greil, Karl-Walter Sykora, Dirk Janssen, Martin Zimmermann, Martin Schrappe, Alfred Reiter
Journal: Blood (2005)
Senior surgeon’s conviction for manslaughter is quashed
Authors: Clare Dyer
Journal: BMJ (2016)

David Sellu, a senior colorectal surgeon who was jailed for gross negligence manslaughter after a patient died, has had his conviction quashed by the Court of Appeal.1

Three judges ruled that the conviction was unsafe because the trial judge’s direction to the jury was inadequate, failing to help them identify when negligence was so serious as to be criminal.

The patient, 66 year old James Hughes, was recovering after a routine knee replacement on 5 February 2010 at the private Clementine Churchill Hospital in Harrow, north London, when he developed abdominal pains as a result of a perforated bowel.

Sellu, who operated at the hospital in addition to his role as an NHS surgeon, was called in on 11 February …
Low Dose Rituximab and Plasma Exchange As Frontline Therapy for Patients with Thrombotic Thrombocytopenic Purpura
Authors: Alberto Vazquez Mellado, Olga Graciela Cantu-Rodriguez, Myrna Pequeño-Luévano, Laura Villarreal-Martínez, José Carlos Jaime-Pérez, Andres Gomez-De-Leon, Oscar Gonzalez-Llano, Perla Colunga-Pedraza, Guillermo Sotomayor-Duque, David Gomez-Almaguer
Journal: Blood (2015)
Novel Mutations in Types 2 &amp; 3 von Willebrand Disease and Correlation with von Willebrand Factor Multimer Patterns.
Authors: Ruetima Titapiwatanakun, Jennifer C. Guenther, Yan W. Asmann, Todd M. Daniels, John A. Heit, William L. Nichols, Rajiv K. Pruthi
Journal: Blood (2007)
A WHO Classification-Based Prognostic Scoring System (WPSS) for Predicting Survival in Myelodysplastic Syndromes.
Authors: Luca Malcovati, Ulrich Germing, Andrea Kuendgen, Matteo G. Della Porta, Rosangela Invernizzi, Aristoteles Giagounidis, Barbara Hildebrandt, Paolo Bernasconi, Sabine Knipp, Mario Lazzarino, Corinna Strupp, Mario Cazzola
Journal: Blood (2005)
Overexpression of RANKL by invariant NKT cells enriched in the bone marrow of patients with multiple myeloma
Authors: E Spanoudakis, M Papoutselis, E Terpos, M A Dimopoulos, C Tsatalas, D Margaritis, A Rahemtulla, I Kotsianidis, A Karadimitris
Journal: Blood Cancer Journal (2016)

Overexpression of RANKL by invariant NKT cells enriched in the bone marrow of patients with multiple myeloma
THU0096 Serum Inflammation Identifies Increased Risk of Frailty in Rheumatoid Arthritis: Table 1.
Authors: J. Andrews, E. Wahl, G. Schmajuk, E. Yelin, P. Katz
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Frailty is defined as "excess vulnerability to stressors, with reduced ability to maintain or regain homeostasis after a destabilizing event"<sup>1</sup>. Frailty is closely related to body composition and physical functioning, and is associated with increased risk of poor health outcomes including death. Serum inflammation is associated with differences in body composition and physical functioning in the general population and individuals with chronic disease. The ability of serum markers of inflammation to identify increased frailty among individuals with rheumatoid arthritis (RA) is unknown. <h3>Objectives</h3> We tested whether serum erythrocyte sedimentation rate (ESR) and C-Reactive Protein (CRP) are associated with increased risk of frailty among men and women with RA. <h3>Methods</h3> Participants were individuals in a longitudinal RA cohort. ESR and high sensitivity CRP were assessed from blood samples using standard clinical assays. Individuals with 3 or more of the following physical deficits were classified as frail<sup>1</sup>: 1) body mass index ≤18.5, 2) low grip strength (adjusted for sex and BMI, measured by handheld dynamometer), 3) severe fatigue (measured by the Fatigue Severity Inventory), 4) slow 4-meter walking speed (adjusted for sex and height), 5) low physical activity (measured by the International Physical Activity Questionnaire). Individuals with 1 or 2 deficits were classified as pre-frail, and those with no deficits as robust.<sup>1</sup> Multinomial logistic regression analyses controlling for age, sex, smoking status, RA disease duration, prednisone use, tumor necrosis factor inhibitor use, appendicular lean mass, and pain modeled the effects of ESR and CRP on severity of frailty. <h3>Results</h3> Of the 141 participants, 60% were female; mean age was 58 (±11) years, duration of RA was 19 (±11) years, ESR was 19 (±19) mm/h, and hsCRP was 5 (± 8) mg/L. Sixteen participants (11%) were frail, 86 (61%) pre-frail, 22 (16%) robust, and 17 (12%) were missing grip strength data. In adjusted models, higher ESR was associated with significantly increased risk of frailty (Table 1). Similar trends were observed between CRP and risk of frailty, but did not reach statistical significance in adjusted models. <h3>Conclusions</h3> Frailty and pre-frailty were common in our cohort of individuals with RA, with a greater prevalence than that of geriatric populations. ESR levels were associated with approximately twice the risk of being frail or pre-frail compared to being robust. CRP demonstrated similar effects on risk of frailty, though trends did not reach statistical significance. These findings underscore the burden of frailty among individuals with RA, and they may suggest a clinical role for serum ESR and CRP to identify individuals with RA at greatest risk of frailty. <h3>References</h3> Fried J Am Geriatr Soc 2001;56:M146 <h3>Disclosure of Interest</h3> None declared
Six vs. Eight Cycles of Bi-Weekly CHOP-14 with or without Rituximab for Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of the Completed RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).
Authors: Michael Pfreundschuh, Marita Kloess, Samira Zeynalova, Eva Lengfelder, Astrid Franke, Marcel Reiser, Hjalmar Steinhauer, Michael Clemens, Christina Nickenig, Maike de Wit, Bernd Metzner, Manfred Hensel, Hans-Guenther Mergenthaler, Ruediger Liersch, Ulrich Duehrsen, Leopold Balleisen, Monika Engelhardt, Viola Poeschel, Joerg Schubert, Lorenz Truemper, Norbert Schmitz, Markus Loeffler
Journal: Blood (2006)
Mesenchymal Stromal Cells Genetically Engineered To Overexpress Insulin-Like Growth Factor-1 Provide Paracrine Support for Cell-Based Erythropoietin Therapy of Chronic Renal Failure-Induced Anemia.
Authors: Terrence Kucic, Ian B. Copland, Jessica Cuerquis, Daniel L. Coutu, Lorraine E. Chalifour, Raymonde F. Gagnon, Jacques Galipeau
Journal: Blood (2007)